Biogen (BIIB) Finished Goods (2010 - 2018)
Biogen (BIIB) posted quarterly Finished Goods of $133.5 million for Q4 2018, down 15.18% year-over-year from $157.4 million in Q4 2017, and down 15.18% on a QoQ basis from $157.4 million in Q4 2017.
Biogen (BIIB) Finished Goods (2010 - 2018) Analysis & Trends
Biogen (BIIB) has reported Finished Goods for 9 consecutive years, with $133.5 million the latest figure, recorded in Q4 2018.
- In Q4 2018, Finished Goods fell 15.18% year-over-year to $133.5 million; the TTM figure through Dec 2018 stood at $133.5 million (down 15.18% YoY), while the FY2018 annual figure was $133.5 million, down 15.18% from the prior year.
- Finished Goods came in at $133.5 million for Q4 2018 at Biogen, down from $157.4 million in the prior quarter.
- The five-year high for Finished Goods was $170.3 million in Q4 2016, with the low at $133.5 million in Q4 2018.
- Average Finished Goods over 5 years is $153.7 million, with a median of $157.4 million recorded in 2017.
- Across the five-year window, Finished Goods soared 51.2% in 2014 and retreated 15.18% in 2018, its largest moves.
- Year by year, Finished Goods stood at $164.2 million in 2014, then fell by 12.91% to $143.0 million in 2015, then grew by 19.09% to $170.3 million in 2016, then retreated by 7.57% to $157.4 million in 2017, then dropped by 15.18% to $133.5 million in 2018.
- According to Business Quant data, Finished Goods over the past three periods registered $133.5 million, $157.4 million, and $170.3 million for Q4 2018, Q4 2017, and Q4 2016 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 133.50 Mn |
| Dec 31, 2017 | 157.40 Mn |
| Dec 31, 2016 | 170.30 Mn |
| Dec 31, 2015 | 143.00 Mn |
| Dec 31, 2014 | 164.20 Mn |
| Dec 31, 2013 | 108.60 Mn |
| Mar 31, 2013 | 120.70 Mn |
| Dec 31, 2012 | 100.70 Mn |
| Jun 30, 2012 | 103.20 Mn |
| Mar 31, 2012 | 83.30 Mn |
| Dec 31, 2011 | 73.60 Mn |
| Dec 31, 2010 | 230.10 Mn |